Kadmon Holdings Inc (NASDAQ:KDMN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday. The firm presently has a $3.75 price target on the stock. Zacks Investment Research’s target price would suggest a potential upside of 3.59% from the company’s previous close.
According to Zacks, “Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Holdings, Inc. is headquartered in New York. “
A number of other brokerages also recently issued reports on KDMN. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of Kadmon Holdings in a report on Wednesday, February 1st. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $23.00 price target (down from $36.10) on shares of Kadmon Holdings in a report on Thursday, March 23rd. WBB Securities raised Kadmon Holdings from a “sell” rating to a “hold” rating and set a $3.25 price target for the company in a report on Thursday, March 16th. Finally, Citigroup Inc decreased their price target on Kadmon Holdings from $6.00 to $4.00 and set a “neutral” rating for the company in a report on Monday, March 27th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Kadmon Holdings has an average rating of “Buy” and a consensus price target of $12.14.
Shares of Kadmon Holdings (NASDAQ:KDMN) traded down 3.72% during mid-day trading on Tuesday, hitting $3.62. The stock had a trading volume of 565,734 shares. The firm’s market cap is $187.68 million. The firm has a 50 day moving average price of $3.66 and a 200 day moving average price of $5.12. Kadmon Holdings has a 52-week low of $3.10 and a 52-week high of $10.48.
In other news, major shareholder Daniel S. Loeb bought 1,488,095 shares of the business’s stock in a transaction dated Monday, March 13th. The shares were acquired at an average price of $3.36 per share, for a total transaction of $4,999,999.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Several hedge funds have recently bought and sold shares of KDMN. State Street Corp boosted its position in shares of Kadmon Holdings by 66.9% in the fourth quarter. State Street Corp now owns 72,514 shares of the company’s stock valued at $389,000 after buying an additional 29,076 shares during the period. Omega Advisors Inc. bought a new position in shares of Kadmon Holdings during the third quarter valued at about $679,000. Goldentree Asset Management LP bought a new position in shares of Kadmon Holdings during the third quarter valued at about $1,529,000. Beach Point Capital Management LP bought a new position in shares of Kadmon Holdings during the third quarter valued at about $1,480,000. Finally, Macquarie Group Ltd. bought a new position in shares of Kadmon Holdings during the fourth quarter valued at about $2,696,000.
Kadmon Holdings Company Profile
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Get a free copy of the Zacks research report on Kadmon Holdings (KDMN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com